Truist Securities Assumes Perspective Therapeutics at Buy, Raises Price Target to $12
Benzinga Newsdesk 11 months ago
NewsPrice TargetInitiationAnalyst Ratings
Truist Securities analyst Gregory Renza assumes Perspective Therapeutics (AMEX:CATX) with a Buy rating and raises Price Target to $12.
Truist Securities analyst Gregory Renza assumes Perspective Therapeutics (AMEX:CATX) with a Buy rating and raises Price Target to $12.